Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azvudine for COVID-19 Delta infection
ChiCTR2100052875Phase 3Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of azvudine in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by The First Affiliated Hospital of Zhengzhou University. Primary endpoints: Time and rate of temperature return to normal, Time and rate of improvement of respiratory symptoms and signs and 12 more. Planned start Nov 2021; status: not yet recruiting.
02
Drugs
azvudine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2100052875.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100052875.